Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T19:56:17.134Z.
Calculation as of: 2026-10-06T19:56:17.134Z.
Quote observation: 2026-10-06T19:32:36.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5275dea95979b783385bf47589e59696b88cb0a7810ad834bc8fbd7b091458bc
PEG RATIO
N/A
CNS Pharmaceuticals, Inc.
Market Cap
$7.75M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| CNS Pharmaceuticals, Inc. (CNSP) | $7.75M | N/A |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.74M | N/A |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.63M | N/A |
| Traws Pharma, Inc. (TRAW)vs › | $7.92M | N/A |
| Aprea Therapeutics, Inc. (APRE)vs › | $7.94M | N/A |
| Skye Bioscience, Inc. (SKYE)vs › | $7.16M | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.53M | N/A |
| HeartSciences Inc. (HSCS)vs › | $8.12M | N/A |
| GT Biopharma, Inc. (GTBP)vs › | $8.12M | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
